Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Olympus Corp (7733 JP): Forex Holds FY25 Together; FY26 Guidance Does Not Offer Much Respite

Olympus Corp (7733 JP): Concerns Remain; Green Shoots Appear; Better To Wait and Watch

Olympus Corp (7733 JP): A Much-Awaited Turnaround On the Cards? One Quarter At a Time

Olympus Corp (7733 JP): ¥100B Buyback Plan Offers an Attractive Exit Opportunity Amid Bleak Outlook

Olympus Corp (7733 JP): One-Off Events Boost H1FY25 Result; Not Optimistic About FY25 Guidance

Olympus Corp (7733 JP): Q3 Operating Profit Misses Estimates Despite Sales Beat; FY24 Guidance Cut

Equity Bottom-Up

<ul>
<li>Favorable Fx contributed positively in 9MFY25. On a Fx neutral basis, revenue growth is only 3% YoY, while adjusted operating profit growth is flat YoY.</li>
<li>Quality related expenses mar amidst another round of recall by FDA. China drags the profitability. </li>
<li>Olympus revised FY25 revenue guidance from ¥1,009B to ¥997.5B. Downward revision in profits too.</li>
</ul>


Favorable Fx contributed positively in 9MFY25. On a Fx neutral basis, revenue growth is only 3% YoY, while adjusted operating profit growth is flat YoY.
Quality related expenses mar amidst another round of recall by FDA. China drags the profitability. 
Olympus revised FY25 revenue guidance from ¥1,009B to ¥997.5B. Downward revision in profits too.


Olympus Corp (7733 JP): Fx Holds Turf in 9MFY25 Amid Subdued China; FY25 Guidance Revised Downward